Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Result Preview
Ranbaxy Laboratories – 4QCY2010
Ranbaxy Laboratories (Ranbaxy) is scheduled to announce its 4QCY2010 results. We expect
the company to post a flat top line of `2,245cr. Growth looks muted despite the launch of
Aricept in the US, on the back of high base during the last corresponding period due to sales
of Valtrex. For Aricept, we expect the company to post sales of around US $240mn during
the exclusivity period. However, the impact of the same would be more visible in 1QCY2011.
On the operating front, Ranbaxy is expected to report OPM of 17.4%. Overall, the company
is expected to post net profit of `312.6cr. We currently remain Neutral on the stock.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Result Preview
Ranbaxy Laboratories – 4QCY2010
Ranbaxy Laboratories (Ranbaxy) is scheduled to announce its 4QCY2010 results. We expect
the company to post a flat top line of `2,245cr. Growth looks muted despite the launch of
Aricept in the US, on the back of high base during the last corresponding period due to sales
of Valtrex. For Aricept, we expect the company to post sales of around US $240mn during
the exclusivity period. However, the impact of the same would be more visible in 1QCY2011.
On the operating front, Ranbaxy is expected to report OPM of 17.4%. Overall, the company
is expected to post net profit of `312.6cr. We currently remain Neutral on the stock.
No comments:
Post a Comment